Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Toxicology Databases, FDA & Industry Aim To Use, Not Lose, Safety Data

Executive Summary

Both FDA and industry are organizing databases to make the toxicities of known compounds available to the researchers making decisions in early development. Those efforts at computational toxicology are being met with a great deal of excitement

You may also be interested in...



Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA

The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference

Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA

The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference

Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test

The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial

Latest News
See All
UsernamePublicRestriction

Register

PS050252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel